Themis Medicare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹90 Cr +15.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
TM

Themis Medicare Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Themis Medicare Q4 FY26: Revenue ₹76.53 Cr, PAT ₹8.89 Cr

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹77Cr
+6.7% YoY
−15.1% QoQ
Net profit
₹9Cr
Turned profitable YoY
−11.9% QoQ
Margin
4.91%
+15.7 pp YoY
−6 pp QoQ

Based on Themis Medicare Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹118
Market cap₹1.1K Cr

The short version

Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Q4 FY26 EBITDA: ₹3.76 crore (up from a loss of ₹5.78 crore in Q4 FY25), margin 4.92% (vs. -8.07% YoY).

From Themis Medicare Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8).
  • FY26 Net Revenue: ₹342.24 crore, down 15.6% YoY from ₹405.51 crore in FY25 (Page 9).
  • Quarterly Revenue trend: Q1 FY26 ₹97.6 crore, Q2 FY26 ₹78.0 crore, Q3 FY26 ₹90.1 crore, Q4 FY26 ₹76.5 crore (Page 7).

2 more points from Themis Medicare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The presentation mentions vertically integrated manufacturing facilities at Haridwar, Hyderabad, and Vapi with state-of-art capabilities for formulations and synthetic APIs.
  • Capacity details:
  • Formulations (Haridwar): Tablets (520 mn), Ointments (9 mn tubes), Ampoules (36 mn), Vials (12 mn), Pre-filled syringes (6 mn) per annum.

2 more points from Themis Medicare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Specifically: - Focus is on financial results, business segments, strategic initiatives, R&D, manufacturing capacity, aspirations, and contact information. - Performance data pertains to revenue, profit, and expenses rather than order-related metrics.

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Themis Medicare Ltd Q4 FY26 results — key figures

Themis Medicare Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue7772+6.7%90-15.1%
Operating profit (EBITDA)4-8—10-61.6%
Operating margin4.91%-10.74%+15.7 pp10.87%-6 pp
Profit before tax9-11—10-12.8%
Net profit (PAT)9-10—10-11.9%
EPS (₹)0.97-1.05—1.10-11.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Themis Medicare Ltd Q4 FY26 results?

Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Q4 FY26 EBITDA: ₹3.76 crore (up from a loss of ₹5.78 crore in Q4 FY25), margin 4.92% (vs. -8.07% YoY).

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Is Themis Medicare Ltd planning capital expenditure?

The presentation mentions vertically integrated manufacturing facilities at Haridwar, Hyderabad, and Vapi with state-of-art capabilities for formulations and synthetic APIs.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.